BRICANYL
LOE ApproachingNDAORALTABLET
Approved
Apr 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRICANYL is an oral tablet small-molecule therapeutic approved by the FDA in 1975 under NDA designation by Sanofi. The specific indication and mechanism of action are not publicly available in current data, limiting clinical characterization. This product represents a legacy small-molecule asset in the Sanofi portfolio.
LOE Approaching
LOE-approaching status with moderate competitive pressure (30/100) suggests contracting revenue and downsizing commercial infrastructure over the next 2–3 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
Started Mar 2015
95 enrolled
Asthma
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
Started Sep 2009
66 enrolled
Exercise Induced Asthma
Career Relevance
Zero linked job openings reflect the LOE-approaching lifecycle; career opportunities are shrinking as the product approaches generic erosion. Working on BRICANYL now focuses on maximizing remaining exclusivity window and managing profitable decline rather than growth.
Worked on BRICANYL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.